Insider Selling: InspireMD (NYSE:NSPR) Insider Sells 9,923 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 9,923 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $2.55, for a total value of $25,303.65. Following the completion of the sale, the insider owned 1,116,806 shares in the company, valued at $2,847,855.30. This represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The shares were sold at an average price of $1.01, for a total value of $23,005.78.

InspireMD Stock Up 3.0%

InspireMD stock traded up $0.03 during midday trading on Thursday, reaching $1.03. The stock had a trading volume of 160,140 shares, compared to its average volume of 182,457. InspireMD, Inc. has a 12 month low of $0.97 and a 12 month high of $2.93. The firm’s 50-day moving average price is $1.40 and its 200 day moving average price is $1.68. The firm has a market capitalization of $48.24 million, a PE ratio of -1.37 and a beta of 0.82.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 target price (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Loop Capital set a $5.00 price objective on InspireMD in a report on Tuesday, February 24th. Maxim Group initiated coverage on InspireMD in a report on Monday, February 2nd. They set a “buy” rating and a $6.00 price objective for the company. Finally, Lake Street Capital set a $4.00 price objective on InspireMD in a report on Monday, May 4th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $4.50.

Hedge Funds Weigh In On InspireMD

A number of institutional investors have recently bought and sold shares of NSPR. Renaissance Technologies LLC purchased a new position in shares of InspireMD during the 1st quarter worth approximately $29,000. Virtu Financial LLC purchased a new position in shares of InspireMD in the 4th quarter valued at approximately $31,000. XTX Topco Ltd purchased a new position in shares of InspireMD in the 4th quarter valued at approximately $30,000. Orbimed Advisors LLC boosted its position in shares of InspireMD by 46.9% during the fourth quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock valued at $5,577,000 after purchasing an additional 1,000,000 shares in the last quarter. Finally, Essex Investment Management Co. LLC bought a new stake in shares of InspireMD during the fourth quarter valued at approximately $203,000. 44.78% of the stock is owned by institutional investors.

Key InspireMD News

Here are the key news stories impacting InspireMD this week:

• Neutral Sentiment: Shane Thomas Gleason disclosed multiple recent sales of InspireMD shares, including transactions on May 19, May 23, May 27, May 29, May 30, and earlier January/February dates. Each filing says the sales were made to cover tax withholding obligations related to the vesting of equity awards, which makes the activity look more routine than a strategic exit. Article Title
• Neutral Sentiment: A new “Stock Forecast & Price Target” page for InspireMD may be contributing to increased trading interest, but the item itself does not include a specific rating change, earnings update, or business development that would clearly drive the shares. Article Title

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.